Greenwood Capital Associates LLC Has $798,000 Stake in STERIS plc (NYSE:STE)

Greenwood Capital Associates LLC decreased its position in shares of STERIS plc (NYSE:STE) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,289 shares of the medical equipment provider’s stock after selling 75 shares during the period. Greenwood Capital Associates LLC’s holdings in STERIS were worth $798,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of STE. J.Safra Asset Management Corp raised its position in shares of STERIS by 77.9% during the first quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 53 shares during the last quarter. Central Pacific Bank Trust Division acquired a new position in shares of STERIS during the third quarter valued at about $28,000. Quent Capital LLC raised its position in shares of STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 71 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of STERIS during the first quarter valued at about $36,000. Finally, Versant Capital Management Inc raised its position in shares of STERIS by 2,262.5% during the second quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock valued at $41,000 after buying an additional 181 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Price Performance

Shares of STERIS stock opened at $227.44 on Wednesday. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $22.43 billion, a price-to-earnings ratio of 56.44 and a beta of 0.85. STERIS plc has a 1-year low of $195.47 and a 1-year high of $248.24. The firm’s 50-day moving average price is $233.36 and its two-hundred day moving average price is $227.60.

STERIS (NYSE:STE) last issued its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.16. The firm had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.00 earnings per share. On average, equities analysts predict that STERIS plc will post 9.02 earnings per share for the current fiscal year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Tuesday, November 19th. This represents a $2.28 annualized dividend and a dividend yield of 1.00%. STERIS’s dividend payout ratio (DPR) is currently 56.58%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on STE shares. Stephens reaffirmed an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and upped their target price for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research note on Wednesday, August 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $253.00.

Insider Activity

In other news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the sale, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christopher S. Holland sold 473 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the transaction, the director now owns 582 shares in the company, valued at $139,493.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.